S. S. Yakushin

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Roy Fleischmann, Eduardo Mysler, Stephen Hall et al. · The Lancet · 2017 · 479 citations

Rheumatoid Disorder, Rheumatology, Tofacitinib Monotherapy +8

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 349 citations · Full text

Inflammation, Rheumatology, Rheumatoid Disorder +14

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler et al. · The Lancet · 2019 · 208 citations

Rheumatology, Spondyloarthritis, Rheumatic Diseases +8

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

Sean D. Pokorney, Jonathan P. Piccini, Susanna R. Stevens et al. · Journal of the American Heart Association · 2016 · 196 citations · Full text

Disorders of lipid metabolism. Clinical Guidelines 2023

G. Arabidze, Aronov Dm, G. P. Arutyunov et al. · Russian Journal of Cardiology · 2023 · 174 citations · Full text

Family Medicine, Metabolic Disorder, Hyperlipidemia +16